Biofrontera Inc. and Biofrontera AG Negotiate Fundamental Changes to Cooperation

Biofrontera Inc. is in negotiations with Biofrontera AG regarding a potential combination of the two companies or changes to their license and supply agreement. This could involve the transfer of certain rights and obligations from AG to Inc. and a reduced transfer price for licensed products sold in the US. The terms have not been established and are subject to conditions, including negotiation and execution of definitive agreements.

Biofrontera Inc. (BFRI) and Biofrontera AG are engaged in negotiations regarding potential significant changes to their business relationship. The discussions center around two possible outcomes: a merger between the companies or modifications to their existing license and supply agreement [1].

The negotiations, confirmed by both companies, involve the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. Additionally, the agreement could result in a reduction in transfer pricing for Biofrontera Inc.'s US-licensed products. The terms of any such agreement have not been established yet and are subject to various conditions, including the negotiation and execution of definitive agreements between both parties [2][3][4].

Biofrontera Inc., based in the United States, is a biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions, and non-melanoma skin cancers [5].

Biofrontera AG, based in Germany, is also a biopharmaceutical company focused on PDT. The company's products are sold in the US through Biofrontera Inc. The negotiations could potentially lead to a fundamental adjustment of Biofrontera AG's business model and strategic orientation [6].

The negotiations come at a time when Biofrontera Inc. is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne. The company's forward-looking statements highlight the potential risks and uncertainties associated with the negotiations, including the impact of external events, changes in the company's relationships with licensors, and the ability to achieve profitability [7].

Investors and financial professionals should closely monitor the developments in these negotiations as they could have significant implications for the future of both companies. The final terms of the agreement, if reached, will likely be subject to regulatory approval and other conditions.

References:
[1] https://www.tradingview.com/news/reuters.com,2025-06-11:newsml_GNX30wpdP:0-biofrontera-inc-is-negotiating-fundamental-changes-to-its-cooperation-with-biofrontera-ag/
[2] https://www.tradingview.com/news/reuters.com,2025-06-10:newsml_PexddQZba:0-pta-adhoc-biofrontera-ag-biofrontera-ag-is-negotiating-fundamental-changes-to-its-cooperation-with-biofrontera-inc/
[3] https://www.tradingview.com/news/reuters.com,2025-06-10:newsml_PexTpBlKa:0-biofrontera-ag-is-negotiating-fundamental-changes-to-its-cooperation-with-biofrontera-inc/
[4] https://www.stocktitan.net/news/BFRI/biofrontera-inc-is-negotiating-fundamental-changes-to-its-fwhjlysf7lh4.html
[5] https://www.biofrontera-us.com
[6] https://www.biofrontera.com
[7] https://www.biofrontera-us.com/ir/